[go: up one dir, main page]

BR9810292A - Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor - Google Patents

Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor

Info

Publication number
BR9810292A
BR9810292A BR9810292-3A BR9810292A BR9810292A BR 9810292 A BR9810292 A BR 9810292A BR 9810292 A BR9810292 A BR 9810292A BR 9810292 A BR9810292 A BR 9810292A
Authority
BR
Brazil
Prior art keywords
alpha
insulin secretagogue
thiazolidinedione
glucosidase inhibitor
diabetes treatment
Prior art date
Application number
BR9810292-3A
Other languages
Portuguese (pt)
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9810292A publication Critical patent/BR9810292A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"TRATAMENTO DE DIABETE COM TIAZOLIDINADIONA, SECRETAGOGO DE INSULINA E INIBIDOR DE ALFA-GLICOSIDADE" Descreve-se um método para o tratamento de diabete melito e condições associadas a diabete melito em um mamífero, método esse que compreende administrar uma quantidade eficaz, atóxica e farmaceuticamente aceitável de um sensibilizador de insulina, um secretagogo de insulina, e um agente anti-hiperglicêmico inibidor de alfa-glicosidase, a um mamífero que dela necessite; e a composição para uso nesse método."TREATMENT OF DIABETES WITH THIAZOLIDINADIONA, INSULIN SECRETAGOGUE AND ALPHA-GLYCOSITY INHIBITOR" A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal is described, a method which comprises administering an effective, non-toxic and pharmaceutically effective amount. an insulin sensitizer, an insulin secretagogue, and an alpha-glucosidase inhibiting anti-hyperglycemic agent, to a mammal in need thereof; and the composition for use in that method.

BR9810292-3A 1997-07-18 1998-07-16 Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor BR9810292A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Publications (1)

Publication Number Publication Date
BR9810292A true BR9810292A (en) 2000-09-19

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810292-3A BR9810292A (en) 1997-07-18 1998-07-16 Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor

Country Status (27)

Country Link
EP (1) EP1001784A1 (en)
JP (1) JP2001510160A (en)
KR (1) KR20010021952A (en)
CN (1) CN1263467A (en)
AP (1) AP2000001735A0 (en)
AR (2) AR016350A1 (en)
AU (1) AU8449098A (en)
BG (1) BG104062A (en)
BR (1) BR9810292A (en)
CA (1) CA2297133A1 (en)
CO (1) CO4940489A1 (en)
DZ (1) DZ2563A1 (en)
EA (1) EA200000140A1 (en)
GB (1) GB9715298D0 (en)
HU (1) HUP0003626A3 (en)
ID (1) ID23804A (en)
IL (1) IL133907A0 (en)
MA (1) MA24608A1 (en)
NO (1) NO20000230D0 (en)
OA (1) OA11312A (en)
PE (1) PE99499A1 (en)
PL (1) PL338140A1 (en)
SK (1) SK612000A3 (en)
TR (1) TR200000133T2 (en)
UY (1) UY25101A1 (en)
WO (1) WO1999003478A1 (en)
ZA (1) ZA986364B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
EP1741447B1 (en) * 2000-01-21 2013-09-18 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2001062295A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Drugs containing combined active ingredients
JP4917712B2 (en) * 2000-02-24 2012-04-18 武田薬品工業株式会社 Concomitant medication
JP4633329B2 (en) 2001-01-12 2011-02-16 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド Spaced drug delivery system
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
BRPI0414979A (en) 2003-10-31 2006-11-21 Takeda Pharmaceutical solid preparation
CN101103993B (en) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 Hypoglycemic medicine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69219136T2 (en) * 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. LIQUID FOOD CONTAINING 3-GUANIDINOPROPIONIC ACID
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
EA200000140A1 (en) 2000-06-26
UY25101A1 (en) 2000-12-29
CA2297133A1 (en) 1999-01-28
GB9715298D0 (en) 1997-09-24
JP2001510160A (en) 2001-07-31
CO4940489A1 (en) 2000-07-24
CN1263467A (en) 2000-08-16
SK612000A3 (en) 2000-07-11
OA11312A (en) 2003-10-24
NO20000230L (en) 2000-01-17
ZA986364B (en) 2000-01-17
IL133907A0 (en) 2001-04-30
DZ2563A1 (en) 2003-02-15
AR016350A1 (en) 2001-07-04
PE99499A1 (en) 1999-12-18
PL338140A1 (en) 2000-09-25
MA24608A1 (en) 1999-04-01
AR019724A2 (en) 2002-03-13
HUP0003626A2 (en) 2001-05-28
HUP0003626A3 (en) 2001-12-28
EP1001784A1 (en) 2000-05-24
BG104062A (en) 2000-11-30
NO20000230D0 (en) 2000-01-17
WO1999003478A1 (en) 1999-01-28
TR200000133T2 (en) 2000-09-21
AU8449098A (en) 1999-02-10
ID23804A (en) 2000-05-11
KR20010021952A (en) 2001-03-15
AP2000001735A0 (en) 2000-01-16

Similar Documents

Publication Publication Date Title
BR9810172A (en) Treatment of diabetes with thiazolidinedione and metformin
BR9810445A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and diguanide
BR9911656A (en) Pharmaceutical composition, processes for the prevention or treatment of diabetes in a mammal, for the prevention or treatment of diabetic complications in a mammal and for the prevention or treatment of impaired glucose tolerance in a mammal, use of an insulin sensitizer, and, process to reduce the side effects of an insulin sensitizer or / and an anoretic administered to a diabetic mammal
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
MXPA02012763A (en) Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus.
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
BR9810444A (en) Treatment of diabetes with rosiglitazone and insulin
BR9810292A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor
BR9810186A (en) Diabetes treatment with thiazolidinedione and alpha-glycosity inhibitor
KR900007424A (en) Method of using N-acetylglucosamine as a cytoprotective agent and composition thereof
BR9810142A (en) Diabetes treatment with thiazolidinedione and sulfonylurea
EA200000141A1 (en) METHOD OF TREATMENT OF DIABETAS BY THIAZOLIDINDIONE AND SULFONYL URIDE
BR9915214A (en) Combinations containing a beta-agonist and an additional anti-diabetic agent
BR9815220A (en) Use of thiazolidinediones for the treatment of hyperglycemia
BR9815219A (en) Use of thiazolidinediones for the treatment of hyperglycemia
ECSP982541A (en) NEW METHOD OF TREATMENT II
ECSP982592A (en) NEW METHOD OF TREATMENT V
ECSP982593A (en) NEW METHOD OF TREATMENT VI
ECSP982535A (en) NEW TREATMENT METHOD (I)
ECSP982591A (en) NEW METHOD OF TREATMENT IV
AR009470A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BACTERIAL STRAINS AND USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH OR CAUSED BY ALTERATIONS IN THE METABOLISM OF BILE ACIDS, AND USE OF THE SAME.
KR930700109A (en) 4,4 '-[9H-fluorene-9-ylidenebis (methylene)]-bispyrimidine for the treatment of neurological diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.